Equitable Trust Co. decreased its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 25.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,555 shares of the company's stock after selling 14,670 shares during the quarter. Equitable Trust Co. owned approximately 0.12% of Harrow worth $1,461,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Bleakley Financial Group LLC boosted its position in Harrow by 63.1% during the fourth quarter. Bleakley Financial Group LLC now owns 8,770 shares of the company's stock worth $294,000 after acquiring an additional 3,394 shares during the last quarter. Calamos Advisors LLC boosted its position in Harrow by 35.2% during the fourth quarter. Calamos Advisors LLC now owns 11,913 shares of the company's stock worth $400,000 after acquiring an additional 3,103 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Harrow by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock worth $253,000 after acquiring an additional 727 shares during the last quarter. Sonora Investment Management Group LLC acquired a new position in Harrow during the fourth quarter worth about $518,000. Finally, SG Americas Securities LLC boosted its holdings in Harrow by 158.5% in the 4th quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after purchasing an additional 18,815 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.
Analyst Ratings Changes
Several research firms have weighed in on HROW. B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating on the stock in a report on Wednesday, December 4th. HC Wainwright began coverage on shares of Harrow in a report on Thursday, February 6th. They issued a "buy" rating and a $57.00 target price on the stock.
View Our Latest Report on HROW
Harrow Trading Down 4.7 %
Shares of Harrow stock traded down $1.49 on Friday, reaching $30.42. The company had a trading volume of 334,302 shares, compared to its average volume of 332,103. The firm's 50 day moving average price is $33.96 and its two-hundred day moving average price is $39.86. The firm has a market cap of $1.08 billion, a PE ratio of -32.36 and a beta of 0.69. Harrow, Inc. has a 52-week low of $9.30 and a 52-week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.
About Harrow
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Stories
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
